These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 3828396)

  • 1. Polymeric inhibitors of platelet aggregation. II. Copolymers of dipyridamole and related drugs with N-vinylpyrrolidone.
    Bamford CH; Middleton IP; Al-Lamee KG
    Biochim Biophys Acta; 1987 Apr; 924(1):38-44. PubMed ID: 3828396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of molecular structure on the synergistic action of theophylline or dipyridamole derivatives in the prostaglandin-type inhibition of platelet aggregation.
    Bamford CH; Middleton IP; al-Lamee KG
    J Biomater Sci Polym Ed; 1991; 2(1):37-52. PubMed ID: 1863576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymeric inhibitors of platelet aggregation. Synergistic effects and proposals for a new mechanism.
    Bamford CH; Middleton IP; Al-Lamee KG
    Biochim Biophys Acta; 1986 Apr; 886(1):109-18. PubMed ID: 2420369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of the pyrimido-pyrimidine derivatives, dipyridamole and mopidamol, on platelet and vascular cyclooxygenase activity.
    De La Cruz JP; Ortega G; Sánchez de la Cuesta F
    Biochem Pharmacol; 1994 Jan; 47(2):209-15. PubMed ID: 8304965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233.
    Dawicki DD; Agarwal KC; Parks RE
    Thromb Res; 1986 Jul; 43(2):161-75. PubMed ID: 3016942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dipyridamole and its monoglucuronide derivative on adenosine uptake by human platelets and ADP-induced platelet aggregation.
    Subbarao K; Rucinski B; Niewiarowski S
    Biochem Pharmacol; 1977 May; 26(9):906-7. PubMed ID: 861060
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of platelet aggregation in whole blood by dipyridamole and aspirin.
    Heptinstall S; Fox S; Crawford J; Hawkins M
    Thromb Res; 1986 Apr; 42(2):215-23. PubMed ID: 3715801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for an anti-aggregatory effect of adenosine at physiological concentrations and for its role in the action of dipyridamole.
    Edlund A; Sidén A; Sollevi A
    Thromb Res; 1987 Jan; 45(2):183-90. PubMed ID: 3563983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory mechanism of dipyridamole on platelet aggregation ex vivo.
    Fukawa K; Saitoh K; Irino O; Ohkubo K; Hashimoto S
    Thromb Res; 1982 Aug; 27(3):333-40. PubMed ID: 6291192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro.
    Zhao L; Bath P; Heptinstall S
    Br J Pharmacol; 2001 Sep; 134(2):353-8. PubMed ID: 11564653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.
    Sudo T; Ito H; Ozeki Y; Kimura Y
    Br J Pharmacol; 2001 Aug; 133(8):1396-404. PubMed ID: 11498527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AH6809, a prostaglandin DP-receptor blocking drug on human platelets.
    Keery RJ; Lumley P
    Br J Pharmacol; 1988 Jul; 94(3):745-54. PubMed ID: 2460179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus.
    De La Cruz JP; Moreno A; Mérida F; García Campos J; Sánchez de la Cuesta F
    Thromb Res; 1996 Feb; 81(3):327-37. PubMed ID: 8928090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233.
    Tzanakakis GN; Agarwal KC; Vezeridis MP
    Cancer; 1993 Apr; 71(8):2466-71. PubMed ID: 8453569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inihibition of human platelet aggregation by dipyridamole and two related compounds and its modification by acid glycoproteins of human plasma.
    Niewiarowski S; Lukasiewicz H; Nath N; Tai Sha A
    J Lab Clin Med; 1975 Jul; 86(1):64-76. PubMed ID: 1151144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues.
    Matthews JS; Jones RL
    Br J Pharmacol; 1993 Feb; 108(2):363-9. PubMed ID: 8448586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between dipyridamole and prostaglandin E1 with ADP-induced aggregation of rat platelet in whole blood.
    Touqui L; Hatmi M; Vargaftig BB
    Thromb Haemost; 1984 Jul; 51(3):410. PubMed ID: 6541815
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro effect of mopidamol on platelet-subendothelium interaction.
    De La Cruz JP; Villalobos MA; Palacios R; Smith-Agreda JM; Sánchez de la Cuesta F
    Thromb Res; 1995 Jan; 77(1):97-103. PubMed ID: 7701482
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy.
    Tselepis AD; Goudevenos JA; Tambaki AP; Michalis L; Stroumbis CS; Tsoukatos DC; Elisaf M; Sideris DA
    Cardiovasc Res; 1999 Jul; 43(1):183-91. PubMed ID: 10536703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Modulating effects of adenosine on the process of human platelet activation].
    Prokudin VIu; Melkova OM; Karaulov AV; Porodenko NV
    Biull Eksp Biol Med; 1992 Jun; 113(6):606-8. PubMed ID: 1446028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.